Table 4.

ESRD in ALLHAT chlorthalidone, amlodipine, and lisinopril participants

eGFRTotal Number of Events/ Participants10-Yr Rate/100 ParticipantsHR (95% CI)PHR (95% CI)P
CALCALA Compared with CL Compared with C
Total371/14370225/8492215/84883.03.02.91.02 (0.86–1.20) 0.830.98 (0.82–1.15) 0.78
 ≥9039/360626/224523/21761.21.41.21.06 (0.65–1.74) 0.810.98 (0.59–1.65) 0.95
 60–89112/819976/476874/48111.61.71.81.15 (0.86–1.54) 0.341.12 (0.83–1.50) 0.46
 <60220/2565123/1479118/150110.910.99.90.98 (0.79–1.22) 0.870.91 (0.73–1.14) 0.41
Diabetica245/5723156/3407158/33255.15.35.71.06 (0.86–1.29) 0.591.10 (0.90–1.34) 0.35
 ≥9034/179424/110421/10742.02.72.31.12 (0.66–1.89) 0.681.02 (0.59–1.76) 0.94
 60–8976/297652/175559/17223.13.34.31.14 (0.80–1.62) 0.471.35 (0.96–1.89) 0.09
 <60135/95380/54878/52919.019.018.91.06 (0.81–1.40) 0.671.00 (0.76–1.32) 0.99
Nondiabetica110/799361/468952/47861.51.51.10.94 (0.69–1.29) 0.700.79 (0.57–1.09) 0.16
 ≥905/16911/10632/10330.40.10.10.32 (0.04–2.72) 0.300.67 (0.13–3.44) 0.63
 60–8931/484519/277111/28570.70.80.31.06 (0.60–1.87) 0.850.59 (0.30–1.17) 0.13
 <6074/138341/85539/8446.36.65.50.96 (0.65–1.40) 0.820.89 (0.60–1.31) 0.54
  • This study included 31,350 participants. ESRD indicates start of dialysis or renal transplant, on the basis of data from the US Renal Data System. ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; eGFR, estimated GFR; C, chlorthalidone; A, amlodipine; L, lisinopril; HR, hazard ratio; 95% CI, 95% confidence interval.

  • a Baseline history of diabetes or fasting glucose ≥126 mg/dl (or nonfasting glucose ≥200 mg/dl if baseline fasting glucose missing). Participants missing a baseline glucose measure (n=1427) were excluded from diabetic status subgroups